ZZ 2101
Alternative Names: ZZ-2101Latest Information Update: 28 Mar 2023
At a glance
- Originator GBC of the United States
- Developer Zhongze Therapeutics
- Class Drug withdrawal therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Substance-related disorders
Most Recent Events
- 28 Mar 2023 Discontinued - Phase-II for Substance-related disorders in USA (unspecified route) (Zhongze Therapeutics pipeline, March 2023)
- 28 Mar 2023 Discontinued - Preclinical for Substance-related disorders in China (unspecified route) (Zhongze Therapeutics pipeline, March 2023)
- 04 Sep 2021 Phase-II clinical trials in Substance-related disorders in USA (unspecified route) (Zhongze Therapeutics pipeline, March 2022)